While targeting XBP1 presents a promising therapeutic approach, there are several challenges. One major issue is the potential for unintended effects on normal cells, as XBP1 is also essential for normal cellular functions. Furthermore, cancer cells may develop compensatory mechanisms to bypass the inhibition of XBP1, necessitating combination therapies. Understanding the specific context and dependency of different cancers on XBP1 is crucial for developing effective treatments.
